Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Current Deferred Revenue for 5 consecutive years, with $94000.0 as the latest value for Q2 2024.

  • Quarterly Current Deferred Revenue fell 98.24% to $94000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $94000.0 through Jun 2024, down 98.24% year-over-year, with the annual reading at $1.7 million for FY2023, 68.46% down from the prior year.
  • Current Deferred Revenue for Q2 2024 was $94000.0 at Janux Therapeutics, down from $972000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $5.9 million in Q3 2022, with the low at $94000.0 in Q2 2024.
  • Average Current Deferred Revenue over 5 years is $4.0 million, with a median of $5.0 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue surged 164.77% in 2021, then plummeted 98.24% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $2.0 million in 2020, then soared by 164.77% to $5.2 million in 2021, then increased by 4.71% to $5.4 million in 2022, then plummeted by 68.46% to $1.7 million in 2023, then tumbled by 94.49% to $94000.0 in 2024.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $94000.0, $972000.0, and $1.7 million for Q2 2024, Q1 2024, and Q4 2023 respectively.